Onconova Therapeutics Inc.

Onconova Therapeutics, Inc. is a biopharmaceutical business in the clinical stages that focuses on finding and creating treatments for cancer patients. It uses medicines that are molecularly targeted and intended to block particular biological pathways that support the growth of cancer cells. It has two clinical-stage programmes: narazaciclib (ON 123300), a multi-targeted kinase inhibitor used to treat solid tumours and haematological malignancies either alone or in conjunction with existing anti-cancer treatments; and rigosertib, used to treat solid tumours either alone or in combination.

Technical Daily Chart:

Markets are trading in a highly volatile zone currently due to certain macroeconomic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is March 23, 2023. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: The report publishing date is as per the Pacific Time Zone.